Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice

Xiaogang Xiang, Dechun Feng, Seonghwan Hwang, Tianyi Ren, Xiaolin Wang, Eszter Trojnar, Csaba Matyas, Ruidong Mo, Dabao Shang, Yong He, Wonhyo Seo, Vijay H. Shah, Pal Pacher, Qing Xie, Bin Gao

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Background & Aims: Acute-on-chronic liver failure (ACLF) is a clinical syndrome defined by liver failure on pre-existing chronic liver disease. It is often associated with bacterial infection and high short-term mortality. Experimental models that fully reproduce ACLF are lacking, so too are effective pharmacological therapies for this condition. Methods: To mimic ACLF conditions, we developed a severe liver injury model by combining chronic injury (chronic carbon tetrachloride [CCl4] injection), acute hepatic insult (injection of a double dose of CCl4), and bacterial infection (intraperitoneal injection of bacteria). Serum and liver samples from patients with ACLF or acute drug-induced liver injury (DILI) were used. Liver injury and regeneration were assessed to ascertain the potential benefits of interleukin-22 (IL-22Fc) administration. Results: This severe liver injury model recapitulated some of the key features of clinical ACLF, including acute-on-chronic liver injury, bacterial infection, multi-organ injury, and high mortality. Liver regeneration in this model was severely impaired because of a shift from the activation of the pro-regenerative IL-6/STAT3 pathway to the anti-regenerative IFN-γ/STAT1 pathway. The impaired IL-6/STAT3 activation was due to the inability of Kupffer cells to produce IL-6; whereas the enhanced STAT1 activation was due to a strong innate immune response and subsequent production of IFN-γ. Compared to patients with DILI, patients with ACLF had higher levels of IFN-γ but lower liver regeneration. IL-22Fc treatment improved survival in ACLF mice by reversing the STAT1/STAT3 pathway imbalance and enhancing expression of many antibacterial genes in a manner involving the anti-apoptotic protein BCL2. Conclusions: Acute-on-chronic liver injury or bacterial infection is associated with impaired liver regeneration due to a shift from a pro-regenerative to an anti-regenerative pathway. IL-22Fc therapy reverses this shift and attenuates bacterial infection, thus IL-22Fc may have therapeutic potential for ACLF treatment. Lay summary: A mouse model combining chronic liver injury, acute hepatic insult, and bacterial infection recapitulates some of the key features of acute-on-chronic liver failure (ACLF) in patients. Both fibrosis and bacterial infection contribute to the impaired regenerative capacity of the liver in patients with ACLF. Herein, we show that IL-22Fc therapy improves ACLF by reprogramming impaired regenerative pathways and attenuating bacterial infection. Thus, it may have therapeutic potential for patients with ACLF.

Original languageEnglish (US)
Pages (from-to)736-745
Number of pages10
JournalJournal of hepatology
Volume72
Issue number4
DOIs
StatePublished - Apr 2020

Keywords

  • ACLF
  • Bacteria
  • IFN-γ
  • IL-6
  • STAT1
  • STAT3

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice'. Together they form a unique fingerprint.

  • Cite this

    Xiang, X., Feng, D., Hwang, S., Ren, T., Wang, X., Trojnar, E., Matyas, C., Mo, R., Shang, D., He, Y., Seo, W., Shah, V. H., Pacher, P., Xie, Q., & Gao, B. (2020). Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. Journal of hepatology, 72(4), 736-745. https://doi.org/10.1016/j.jhep.2019.11.013